ADAna M. Dopico-Fernandez

Ana M. Dopico-Fernandez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana M. Dopico-Fernandez has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inhibition of MLLT1 Limits Growth of KMT2A::AFF1 Leukemias Without Killing Healthy Hematopoietic Stem Cells

    by Shivani Rajhansa, Nicholas T. Crump, Hwei Minn Khoo, Ana Dopico-Fernandez, Yavor Bozhilov, Paul E. Brennan, Oleg Fedorov, Cassandra Adams, Gillian Farnie, Thomas A. Milne, et al.

  • Open Access

    FACT safeguards promoter topology by maintaining nucleosomes and restricting chromatin factor spreading

    by Ana M. Dopico-Fernandez, Hangpeng Li, Catherine Chahrour, James L.T. Dalgleish, James O.J. Davies, Robert A. Beagrie, Thomas A. Milne

    SUMMARY: Facilitates chromatin transcription (FACT) is a histone chaperone that displaces and re-assembles histones during transcription. Recent studies have reported a minor role for FACT in chromatin architecture. We have recently shown that active gene promoters form nanoscale domains and proposed they are created by the biophysical properties of nucleosome-free regions. Here we use base-pair resolution Micro Capture-C ultra to show that, following FACT degradation, nanoscale domains are lost and subnucleosomal chromatin interactions are rearranged at active promoters. Nucleosome-free regions at these promoters expand and chromatin-binding factors invade the newly accessible chromatin, indicating FACT maintains the integrity of active promoters by opposing DNA-binding factor spreading into gene bodies. Finally, we show increased interactions between promoters across topologically associating domains, suggesting large-scale structural changes upon FACT loss. Thus, we demonstrate FACT plays a major role in chromatin organisation and provide in vivo evidence that nucleosomes drive both local and long-range chromatin architecture.


  • Open Access

    Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients

    by Alastair L. Smith, Nicholas Denny, Catherine Chahrour, Kim Sharp, Marta Arachi, Ana M. Dopico-Fernandez, Natalina Elliott, Joe R. Harman, Thomas Jackson, Huimin Geng, et al.

    Genetic alterations alone cannot account for the diverse phenotypes of cancer cells. Even cancers with the same driver mutation show significant transcriptional heterogeneity and varied responses to therapy. However, the mechanisms underpinning this heterogeneity remain underexplored. Here, we find that novel enhancer usage is a common feature in acute lymphoblastic leukemia (ALL). In particular, KMT2A::AFF1 ALL, an aggressive leukemia with a poor prognosis and a low mutational burden, exhibits substantial transcriptional heterogeneity between individuals. Using single-cell multiome analysis and extensive chromatin profiling, we reveal that much transcriptional heterogeneity in KMT2A::AFF1 ALL is driven by novel enhancer usage. By generating high-resolution Micro Capture-C data in primary patient samples, we identify patient-specific enhancer activity at key oncogenes such as MEIS1 and RUNX2, driving high levels of expression of both oncogenes in a patient-specific manner. Overall, our data show that enhancer heterogeneity is highly prevalent in KMT2A::AFF1 ALL and may be a mechanism that drives transcriptional heterogeneity in cancer more generally.


  • Open Access

    MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia

    by Nicholas T. Crump, Alastair L. Smith, Laura Godfrey, Ana M. Dopico-Fernandez, Nicholas Denny, Joe R. Harman, Joseph C. Hamley, Nicole E. Jackson, Catherine Chahrour, Simone Riva, et al.

    Aberrant enhancer activation is a key mechanism driving oncogene expression in many cancers. While much is known about the regulation of larger chromosome domains in eukaryotes, the details of enhancer-promoter interactions remain poorly understood. Recent work suggests co-activators like BRD4 and Mediator have little impact on enhancer-promoter interactions. In leukemias controlled by the MLL-AF4 fusion protein, we use the ultra-high resolution technique Micro-Capture-C (MCC) to show that MLL-AF4 binding promotes broad, high-density regions of enhancer-promoter interactions at a subset of key targets. These enhancers are enriched for transcription elongation factors like PAF1C and FACT, and the loss of these factors abolishes enhancer-promoter contact. This work not only provides an additional model for how MLL-AF4 is able to drive high levels of transcription at key genes in leukemia but also suggests a more general model linking enhancer-promoter crosstalk and transcription elongation.